共 50 条
Significance of matrix metalloproteinase-9 in cardiac dysfunction during the very acute phase after myocardial infarction in hamsters
被引:8
|作者:
Takai, Shinji
[1
]
Jin, Denan
Inagaki, Sachiko
Yamamoto, Daisuke
Tanaka, Kazuhiko
Miyazaki, Mizuo
机构:
[1] Osaka Med Coll, Dept Pharmacol, Takatsuki, Osaka 5898686, Japan
[2] Osaka Univ Pharmaceut Sci, Dept Clin Pharmacol & Pharmacokinet, Takatsuki, Osaka 5691094, Japan
[3] Osaka Med Coll, Biomed Computat Ctr, Takatsuki, Osaka 5898686, Japan
关键词:
cardiac dysfunction;
inhibitor;
myocardial infarction;
matrix metalloproteinase;
left-ventricular dilatation;
D O I:
10.1016/j.ejphar.2007.07.001
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Matrix metalloproteinase-9 activity is dramatically increased during the acute phase after myocardial infarction. However, the relationship between matrix metalloproteinase-9 activity and cardiac dysfunction is unclear. In 1-day post-myocardial infarction hamsters, matrix metalloproteinase-9 activity was significantly increased, while matrix metalloproteinase-2 activity was not increased. A selective matrix metalloproteinase inhibitor, [2S,4S]-N-Hydroxy-5-ethoxymethyloxy-2-methyl-4-[4-phenoxybenzoyl] aminopentanamide (ONO-4817), significantly suppressed matrix metalloproteinase-9 activity I day after myocardial infarction. ONO-4817 also significantly prevented the development of cardiac dysfunction and left-ventricular dilatation. Matrix metalloproteinase-9 might play a crucial role in cardiac dysfunction and left-ventricular dilatation during the very acute phase after myocardial infarction. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:57 / 60
页数:4
相关论文